Genome-wide association study identifies a role for the progesterone receptor in benign prostatic hyperplasia risk.

Published in: Prostate cancer and prostatic diseases (2020)

Our results suggest that genetic variants identified from BPH GWAS can identify pharmacologic targets for BPH treatment.

Keyphrases